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Background: Chronic hepatitis B (CHB) is a global health problem that can result in serious complications
associated with collagen degradation. Prolidase is a specific imidodipeptidase that plays an important role in the
breakdown of collagen. The aim of this study was to investigate prolidase activity and oxidant–antioxidant status in
children with CHB.
Methods: This prospective case control study includes 38 patients with CHB, 31 patients with inactive hepatitis B
(IHB), and 29 healthy matched control subjects. Serum prolidase enzyme activity (SPEA), total antioxidant capacity
(TAC), total oxidative activity (TOA), and malondialdehyde (MDA) level were measured and oxidative stress index
(OSI) was calculated for each group.
Results: Patients with CHB had significantly higher SPEA levels (207.82 ± 186.80 IU/L) than did the controls
(58.6 ± 38.1 IU/L) and IHB patients (67.1 ± 39.9) (p < 0.001). CHB patients also had significantly higher TOA
(45.0 ± 19.9 vs. 29.4 ± 11.7 (μmolH2O2 Eq./L), p = 0.005), OSI (33.1 ± 21.4 vs. 17.5 ± 10.2, p = 0.002) and MDA
(13.4 ± 4.0 vs. 7.8 ± 2.6 μm/L, p < 0.001) values compared with the controls. TOA (32.0 ± 10.0) and OSI (15.4 ± 11.0)
values of IHB patients were significantly lower than those of CHB patients (p < 0.05). SPEA had significant
correlations with HBV- DNA and ALT values (r =0.514 and r =0.454, p < 0.001).
Conclusion: Our results suggest that prolidase activity can be considered as a reliable marker for CHB and
increased oxidative stress appears to be related to chronicity of the disease.
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The hepatitis B virus (HBV) infection is a worldwide
healthcare problem. According to the World Health
Organization (WHO), approximately two billion people
in the world have been infected by HBV, with more
than 240 million of these having chronic hepatitis B
(CHB) infection [1]. Despite the existence of effective
vaccines and improvements in diagnosis and treatment,
nearly one million CHB patients die every year due to
complications of hepatitis B [2]. It has been reported
that 3–5% of chronic carriers develop cirrhosis and
0.01–0.03% of chronic carriers develop hepatocellular
carcinoma HCC before adulthood [1]. Although these* Correspondence: drvelatsen@hotmail.com
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unless otherwise stated.complications are rare in childhood, previous studies
reported that the disease can cause unfavorable future
consequences [3]. Therefore, physicians should monitor
all children with HBV infection, whether or not they
are symptomatic, with respect to disease progression to
chronicity.
A major clinical question facing the medical commu-
nity today is how to better monitor children with HBV
infection without using invasive techniques. Several me-
thods have already been developed, however, none of
them was validated in pediatric population. Therefore,
non invasive methods that can accurately predict the
severity of liver disease for patient follow up should be
developed.
Prolidase is a cytosolic and multifunctional exo-
peptidase that possesses the unique ability to degrade. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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line or hydroxyproline from oligopeptides [4]. Collagen
is an important substrate of prolidase due to its high
contents of amino acids. It has been shown that serum
prolidase enzyme activity (SPEA) is elevated in condi-
tions that are characterized by chronic inflammation of
the tissue and/or increased turnover of collagen. Previ-
ous studies have investigated prolidase activity in differ-
ent clinical conditions, such as rheumatic diseases [5],
asthma [6], and thalassemia [7]. However, there are few
studies regarding prolidase activity in liver diseases, es-
pecially those in childhood. In one study, plasma proli-
dase was elevated in adults with nonalcoholic fatty liver
disease [8]. In another study, patients with cirrhosis
were found to have increased SPEA levels [9].
Reactive oxygen species (ROS) are produced by the me-
tabolism of normal cells and are thought to play an im-
portant role in a variety of pathophysiological processes
involving increased oxidative stress [10]. The proper bal-
ance between antioxidants and prooxidants is critical for
normal function. An imbalance favoring prooxidants is
defined as oxidative stress. Increased oxidative stress leads
to hepatic tissue damage in liver diseases. It has been pro-
posed that oxidative stress contributes to the progression
and deterioration of damage caused by viral hepatitis [11].
Malondialdehyde (MDA) is one of the most important
end product of free radical reactions. MDA has various
cytotoxic effects, including enzyme inactivation and inhib-
ition of DNA, RNA and protein synthesis, which may re-
sult in chronic viral hepatitis [12].
To our knowledge, there is no published data regarding
prolidase activity in children with HBV infection. There-
fore, our aim in this study was to investigate serum proli-
dase activity, for the first time, as a biochemical marker in
children with HBV infection. In addition, we investiga-
ted oxidative stress markers, including total antioxidant
capacity (TAC), total oxidant activity (TOA), oxidative
stress index (OSI), and malondialdehyde (MDA), in these
children.Materials and methods
Patients
A total of 98 children (38 CHB, 31 inactive hepatitis B,
and 29 healthy controls) who were followed up at the
Pediatric Outpatient Clinics of Dicle University Hospital
were included in this study. The patients were recruited
prospectively between January 2014 and April 2014. The
control group consisted of children who were under-
going routine checkups or presurgical examination for
elective minor surgery, such as inguinal hernia repair or
circumcision. The children in the control group had
normal physical examinations and blood biochemistry
and their medical history gave no findings of systemicillnesses or recent disease. None of these children had
positive hepatitis B serum markers.
The diagnosis of CHB infection was based on the follo-
wing: persistent or intermittently elevated liver enzymes,
serum alanine aminotransferase (ALT) greater than 1.5
times the normal value (less than 40 IU/L), a positive he-
patitis B surface antigen (HBsAg) test result for more than
6 months, and serum HBV DNA >2.000 IU/ml. Patients
were included in the study as inactive HBsAg carriers
(inactive hepatitis B, IHB) if they had the following: a
positive HBsAg longer than 6 months, a negative Hepatitis
B “e” antigen (HBeAg), serum HBV DNA <2.000 IU/ml,
normal ALT and aspartate aminotransferase (AST) levels,
and negative anti-HDV during their follow-up period [13].
Patients underwent regular follow-ups and were se-
lected for assessment of liver function based on pro-
lidase activity and oxidative status. A detailed medical
history and clinical examination were performed in all
patients. They also underwent evaluation for the exist-
ence of diseases other than CHB on presentation. An-
thropometric characteristics, including weight, height
and body mass index (BMI) z-scores were determined
and recorded.
Exclusion criteria
Patients were excluded from the study if they met the
following criteria: aged less than 3 years or more than
17 years; had concomitant diseases that could affect
liver functions or potentially lead to liver damage, such
as autoimmune hepatitis, α1-antitrypsin deficiency and
Wilson disease; diagnosed with malignancy; diagnosed
with hepatitis D and hepatitis C infections; or received
hepatotoxic drugs. Patients were also excluded if they
had a history of suggestive trauma or fracture, systemic
or local infections, juvenile rheumatoid arthritis, find-
ings in favor of other liver and connective tissue dis-
orders, were receiving corticosteroids and non-steroid
anti-inflammatory drugs capable of interfering with free
radical production or SPEA, and liver and kidney fail-
ure. In addition, patients with liver cirrhosis, irrespect-
ive of the etiology, were also excluded.
Biochemical analyses
Patients were advised not to take any medications for
24 hours prior to blood sampling. Blood samples were
withdrawn from an antecubital vein, preferably after an
overnight fast, and were immediately centrifuged at
4,000 rpm at 4°C for 10 min and then transferred into
Eppendorf tubes. Samples were transferred on ice and
stored at −80°C until further analysis.
Baseline laboratory results of all patients were ob-
tained on admission and measured by an enzymatic
colorimetric method by an Abbot ARCHITECT C16000
(Illinois, USA) instrument in the Biochemistry Laboratory.
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AST, gamma glutamyl transferase (GGT) and total bili-
rubin (TBIL). Additionally, Prothrombin Time (PT) and
activated Partial Thromboplastin Time (aPTT) were mea-
sured and complete blood counts were performed. Hepa-
tobiliary ultrasound was performed for all patients.
Measurement of serum prolidase activity
SPEA was determined using a commercially available
quantitative enzyme-linked immune sorbent assay (ELISA)
technique (Hangzhou Eastbiopharm Company, Hangzhou,
China) according to the manufacturer’s instructions.
Measurement of total antioxidant capacity
TAC of the supernatant fractions was determined using
a novel automated measurement method developed by
Erel [14]. In this method, the antioxidative effect of the
sample against potent-free radical reactions (initiated
by a hydroxyl radical) is measured. The results are ex-
pressed as μmol Trolox eq./L.
Measurement of total oxidant activity
TOA of supernatant fractions was determined using a
novel automated measurement method developed by
Erel [15]. The assay is calibrated with hydrogen peroxide
and the results are expressed as μmol H2O2 equiv./L.
Oxidative stress index
OSI indicates the degree of oxidative stress, and is calcula-
ted as follows: OSI (arbitrary units) = [TOA/TAC] × 10014.
Lipid oxidation determination
MDA levels in plasma were measured via high-pressure
liquid chromatography (HPLC) based on differentiation
with dinitrophenylhydrazine [16]. The MDA results are





Age, years 11.4 ± 3.6 12.2 ± 2.7
BMI, z-scores −0.156 ± 1.011 −0.134 ± 0.998
Serum glucose (mg/d L) 93.6 ± 9.1 93.0 ± 11.7
Serum ALB (g/dL) 3.0 ± 0.3 4.0 ± 0.3
TBIL (mg/dL) 0.65 ± 0.93 0.59 ± 0.39
ALT (IU/L) 73.6 ± 64.8* 28.5 ± 12.9
AST (IU/L) 59.9 ± 53.6 27.8 ± 8.3
GGT (IU/L) 35.9 ± 47.8 18.5 ± 9.9
aPTT (second) 28.58 ± 3.23 31.10 ± 11.46
INR 1.09 ± 0.07 1.06 ± 0.08
Data presented as mean ± standard deviation, *p < 0.001vs. inactive hepatitis B and
BMI, body mass index; ALB, albumin; TBIL, total bilirubin, ALT: Alanine aminotransfe
INR: International normalized ratio of prothrombin time; and aPTT: Activated partialOur study was conducted in accordance with the Dec-
laration of Helsinki and approved by the Institutional
Review Board of Dicle University Medical School. Writ-
ten informed consent was obtained from each partici-
pant and/or from his or her legal caregivers prior to
enrolling in the study.
Statistical analysis
Results were expressed as means and standard devia-
tions (SD). A one-sample Kolmogorov-Smirnov test was
used to determine if the data was normally distributed.
Intergroup comparisons were performed, based on data
distribution pattern, using one-way ANOVA or Kruskal-
Wallis test for three independent groups and Student’s
t-test or Mann–Whitney U-test for two independent
groups. Relationships between variables were determined
using the Spearman correlation analysis. P values less than
0.05 were considered statistically significant. All data were
analyzed using the statistical package SPSS 18.0 for
Windows (IBM Corporation, Armonk, NY).
Results
A total of 38 children with CHB (27 boys, 11 girls), 31
with IHB (21 boys, 10 girls), and 29 matched healthy
control subjects (14 boys, 15 girls) were enrolled in this
study between January 2014 and April 2014. The de-
mographic and biochemical characteristics of the study
groups are listed in Table 1. The mean age and age ranges
of the groups were as follows: CHB group, 11.36 ±
3.60 years (range, 3–17); IHB group, 12.22 ± 2.70 years
(range, 6–16); and the control subjects, 11.31 ± 2.73 years
(range, 7–16). There were no significant differences be-
tween the groups in terms of age, gender distribution and
anthropometric measurements (p > 0.05, for all) (Table 1).
The serum glucose, albumin, total protein, total biliru-
bin, and direct bilirubin values of three groups were withintudy groups
B(b) Controls(c) (n = 29) p
11.3 ± 2.7 a-b-cNS
0.240 ± 0.698 a-b-cNS
96.4 ± 14.5 a-b-cNS
4.0 ± 0.2 a-b-cNS
0.41 ± 0.16 a-b-cNS
24.9 ± 6.6 a-b < 0.001, a-c < 0.001, b-cNS, a-b-c < 0.001
25.9 ± 5.8 a-b < 0.001, a-c < 0.001, b-cNS, a-b-c < 0.001
18.9 ± 6.1 a-b-cNS
34.58 ± 15.72 a-b-cNS
1.05 ± 0.06 a-b-cNS
controls.
rase, AST: Aspartate aminotransferase, GGT: Gamma glutamyl transferase,
thromboplastin time, NS: Not significant.
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between them (p > 0.05, for all) (Table 1). In addition,
there were no significant differences between the PT and
aPTT values in children with HBV infection and the con-
trols (p = 0.077 and p = 0.758, respectively) (Table 1).
In the CHB group, serum ALT levels ranged from 6 to
274 IU/L, and 22 (57.9%) of the children in this group
had high (>40 IU/L) ALT values. In addition, 16 (42.1%)
children in the CHB group had high (>40 IU/L) AST
(range, 15–230 IU/L) values; and seven (18.4%) of them
had high (>29 IU/L) GGT (range, 8–180 IU/L) levels.
Seven (22.6%) of the IHB patients had transient mild
ALT elevations (range, 6–59 IU/L, ALT 40–50 IU/L in
5 patients, 50–59 IU/L in two patients). One (3.2%) of
IHB patients had transiently elevated AST (range, 16–
48 IU/L), and GGT (range, 7–53 IU/L) values. During
follow-up elevated ALT, AST and GGT values of IHB
patients returned to normal values. Children with CHB
had significantly higher ALT and AST levels than those
in IHB and the control groups (p < 0.001 for each)
(Table 1).
The HBV DNA values in the CHB group ranged from
12×103 to 170×106 IU/mL, the HBsAg values ranged
from 174 to 5385 IU/mL (positive in all patients), and 3
(7.9%) of these patients had positive AntiHBe. The HBV
DNA values in the IHB group ranged from 100 to
1440 IU/mL, the HBsAg ranged from 100 to 6277 IU/mL,
and 1 (3.3%) of these patients had positive HBeAg. CHB
patients had significantly higher HBV DNA and HBsAg
titers than did the IHB patients (p < 0.001, for each
comparison).
Table 2 summarizes the prolidase activity and serum
markers of oxidative stress (TAC, TOA, OSI and MDA)
in the three groups. Significantly higher SPEA was found
in CHB patients compared with the IHB patients and theTable 2 Prolidase activity and oxidative–antioxidative status
Chronic hepatitis B (n = 38) In
SPEA (IU/L) 207.8 ± 186.8a,e 67
MDA (μm/L) 13.3 ± 4.0a,h 7.
TAC (μmol Trolox Eq t/l) 1.77 ± 0.90b 2.
TOA (μmolH2O2 Eq./L) 45.0 ± 19.9c,f 32
OSI (H2O2/Trolox) 33.1 ± 21.4
d,g 15
CHB: Chronic Hepatitis B, IHB: Inactive Hepatitis B, SPEA: Serum prolidase enzyme a
(Arbitrary Unite): Oxidative stress index, and MDA: Malondialdehyde.
*Difference between three groups with Kruskal-Wallis test.
Differences between pairwise groups with Mann–Whitney U test:
aCompared with group control (p < 0.001).
bCompared with group control (p = 0.004).
cCompared with group control (p = 0.005).
dCompared with group control (p = 0.002).
eCompared with group IHB (p < 0.001).
fCompared with group IHB (p = 0.001).
gCompared with group IHB (p < 0.001).
hCompared with group IHB (p < 0.001).control subjects (p < 0.001, for each) (Table 2). However,
no significant difference was found in SPEA values be-
tween the IHB subjects and the healthy controls (p > 0.05)
(Table 2).
The CHB patients had significantly higher plasma
MDA, TOA, and OSI levels compared with the IHB pa-
tients and the control subjects (p < 0.05) (Table 2). The
TAC levels of the CHB patients were significantly lower
than those of the healthy controls (p = 0.004). However,
no significant differences were found in MDA, TAC, TOA
and OSI levels between CHB and IHB groups (p > 0.05)
(Table 2).
There was a positive significant correlation between
prolidase activity and HBV- DNA values (r =0.514, p <
0.001) in total CHB and IHB patients (n = 69) (Figure 1).
There was also a significant positive correlation between
SPEA and ALT values (r =0.454, p < 0.001) while CHB
and IHB groups were taken as a whole group (n = 69)
(Figure 2). Serum prolidase activity had weak positively
correlations with MDA and OSI (r =0.281, r =0.267,
p < 0.05) (Figures 3 and 4). However, no significant cor-
relations were found between SPEA and TAC or between
SPEA and TOA (p > 0.05 and p = 0.050, respectively)
(n = 69).
HBV-DNA was positively correlated with MDA, TOA
and OSI levels (r = 0.557, r = 0.417, r = 0.497, p < 0.001
for each), and negatively correlated with TAC levels
(r = −0.246, p = 0.042). Significant positive correlations
were found between ALT and MDA levels as well as be-
tween TOA and OSI values (r =0.270, r =0.263, r =0.290,
p < 0.05).
There were no significant correlations between SPEA
and patient age or hematological variables, including he-
moglobin, hematocrit, red blood cell count, and platelet
counts (data not shown, p > 0.05).in the study groups (mean ± standard deviation)
active hepatitis B (n = 31) Controls (n = 29) *p
.1 ± 39.9 58.6 ± 38.1 <0.001
8 ± 3.6 7.8 ± 2.6 <0.001
28 ± 0.88 2.46 ± 0.67 0.015
.0 ± 10.0 29.4 ± 11.7 0.001
.4 ± 11.0 17.5 ± 10.2 <0.001
ctivity, TAC: Total antioxidant capacity, TOA: Total oxidant activity, OSI
Figure 1 The relationship between serum prolidase activity and HBV-DNA (r = 0.514, p < 0.001).
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Hepatitis B virus (HBV) infection is an important disease
worldwide and appropriately monitoring of these pa-
tients is important [17]. Although liver biopsy remains
gold standard for determining disease progression, it is
not practical to perform repeated liver biopsies for all
children who require long-term assessments. Therefore,Figure 2 The relationship between serum prolidase activity and alanidiagnostic and prognostic noninvasive markers are more
appropriate for practical assessments.
To our knowledge, the current study is the first to
demonstrate significantly increased serum SPEA levels
in children with CHB compared with IHB patients and
the healthy controls. The present study is also the first
to evaluate both oxidative status and prolidase activity inne aminotransferase (ALT) (r = 0.454, p < 0.001).
Figure 3 The relationship between serum prolidase activity and oxidative stress index (r = 0.267, p = 0.027).
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enzyme activity and oxidative stress, and decreased anti-
oxidant levels in children with CHB.
The mechanisms of the progression from inactive dis-
ease state to chronicity are not clearly understood. Col-
lagen fibrils act as a frame to support the hepatocytes
and impairment of this structure results in fibrosis [18].
In previous studies, the level of fibrosis has been evaluated
with non-invasive biochemical tests, including N-terminalFigure 4 The relationship between serum prolidase activity and malopropeptide of type III collagen, FibroTest, SteatoTest, and
NashTest [19]. However, some of these tests are not
widely available, and elevated test results have been found
also in several non-specific conditions.
The prolidase enzyme is present in various tissues and
plasma and its physiological role in humans is well-
understood. During protein catabolism, prolidase catalyzes
the degradation of intracellular collagen, and its activity
may be correlated with the rate of collagen degradationndialdehyde (r = 0.281, p = 0.020).
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sues and changes in prolidase activity may play important
roles in extracellular matrix turnover and the development
and outcome of several diseases [21,22]. To our know-
ledge, until the current study, there is no report concern-
ing prolidase activity in pediatric CHB patients.
An increase or decrease in prolidase activity can demon-
strate the existence of a disease state as well as the pro-
gression of the condition. Although some authors suggest
that prolidase activity decreases in some disease condi-
tions, such as asthma [6] and chronic obstructive pul-
monary disease [23], increased prolidase activity has been
reported in some other diseases and cancers [7,24]. SPEA
has been investigated in patients with liver damage, such
as chronic liver diseases [25], alcoholic liver disease [26],
and chronic hepatitis C (CHC) infection [27]. One study
investigated SPEA in patients with nonalcoholic steatohe-
patitis (NASH), and found significantly elevated prolidase
enzyme activity in NASH than simple steatosis. In ad-
dition, some studies have reported a significant correl-
ation between SPEA and stage of liver fibrosis [8].
In and adult study, prolidase levels were found to be
higher in CHB and IHB compared to the control group
and no correlation of prolidase activity was found with
fibrosis, and histological activity index [28]. Our study
included pediatric patients, and therefore, it is different
from previously published studies. Our study evaluated
prolidase activity in CHB and IHB children. We found
higher prolidase activity in CHB children than IHB and
the healthy control group. However, as a limitation of
our study, we did not perform liver histology.
There were significant positive correlations between
the prolidase activity, HBV- DNA, and ALT levels in our
study groups. These correlations may indicate the reli-
ability of serum prolidase measurements and the parallel
changes of these enzyme activities in children with CHB.
The positive correlations that we found between proli-
dase activity and markers of oxidative stress includeing
MDA, TOA, and OSI levels are consistent with the hy-
pothesis that both serum prolidase activity and oxidative
parameters indicate the impairment of hepatic func-
tions [27]. Increased MDA, TOA, and OSI levels and
decreased TAC levels in our study, support the hypoth-
esis that increased oxidative stress may contribute to
the pathogenesis of CHB and the exacerbation of the di-
sease. Indeed, it has been demonstrated that the amount
of ROS in healthy human liver was significantly lower
than found in livers affected by hepatitis B [29]. Recently,
there has been increasing body of evidence proposing that
oxidative stress may play a critical role in various liver dis-
eases, including chronic hepatitis [30]. Our results, which
indicate decreased antioxidant capacity and increased
levels of some important oxidants, such as MDA, are in
accordance with the results of other investigators [10,12].One potential limitation of our study was its cross-
sectional design. However, this is a preliminary study,
which provided information regarding collagen metabol-
ism and oxidative stress in children with CHB by evalu-
ating serum prolidase activity and by determining TAC,
TOA, OSI and MDA.
In conclusion, this study provides novel clinical find-
ings, including a relationship between increased SPEA
and the presence of CHB in children. This may be in-
terpreted as evidence of increased collagen turnover in
CHB. Monitoring serum prolidase activity in clinical
practice may be a suitable and useful method for evalu-
ating hepatitis B advance to chronicity in children. Fur-
ther longitudinal and prospective studies are needed to
clarify the pathophysiological role of serum prolidase ac-
tivity in the progression of the disease process.
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